Literature DB >> 21484239

A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory.

Janice W Smith1, Francois Gastambide, Gary Gilmour, Sophie Dix, Julie Foss, Kirstie Lloyd, Nadia Malik, Mark Tricklebank.   

Abstract

RATIONALE: N-methyl-D: -Aspartate receptor (NMDAR) antagonists such as ketamine induce cognitive symptoms in man similar to those of schizophrenia and therefore might be useful as models of the disease in animals. However, it is unclear which NMDAR antagonist(s) offer the best means to produce cognitive deficits in attention and working memory and to what extent those deficits can be measured selectively in rats.
OBJECTIVES: The present study systematically compared the effects of eight different NMDAR antagonists-MK-801, phencyclidine, (S)-(+)-ketamine, memantine, SDZ-220,581, Ro 25-6981, CP 101-606 and NVP-AAM077-in rats using standard tests of visual attention, the five-choice serial reaction time task (5CSRT), and working memory, the delayed matching to position task (DMTP).
RESULTS: Drug-induced responses varied qualitatively and quantitatively in both a compound- and a task-dependent manner. Effects were generally confounded by concomitant motor and motivational disruption, although individual doses of phencyclidine for example appeared to impair selectively cognitive functions. Interestingly, GluN2B selective antagonists were unique in their effects; inducing potential performance benefit in the 5CSRT.
CONCLUSIONS: Overall, the opportunity to induce a selective cognitive deficit in attention (5CSRT) or working memory (DMTP) in the rat is limited by both the NMDAR antagonist and the dose range used. The importance of a preclinical focus on ketamine, which is used more frequently in clinical settings, is limited by the extent to which cognitive effects can be both detected and quantified using this exposure regimen within these two operant assays.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21484239     DOI: 10.1007/s00213-011-2277-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  50 in total

1.  Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine.

Authors:  Shawn E Kotermanski; Jon W Johnson
Journal:  J Neurosci       Date:  2009-03-04       Impact factor: 6.167

2.  Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment.

Authors:  Nurith Amitai; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2008-09-08       Impact factor: 3.533

3.  Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats.

Authors:  S B Dunnett
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

4.  Neuropsychological profiles delineate distinct profiles of schizophrenia, an interaction between memory and executive function, and uneven distribution of clinical subtypes.

Authors:  S Kristian Hill; J Daniel Ragland; Ruben C Gur; Raquel E Gur
Journal:  J Clin Exp Neuropsychol       Date:  2002-09       Impact factor: 2.475

5.  Low doses of memantine disrupt memory in adult rats.

Authors:  Catherine Creeley; David F Wozniak; Joanne Labruyere; George T Taylor; John W Olney
Journal:  J Neurosci       Date:  2006-04-12       Impact factor: 6.167

6.  Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat.

Authors:  Guy A Higgins; Theresa M Ballard; Michel Enderlin; Marie Haman; John A Kemp
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

Review 7.  Neurocognitive allied phenotypes for schizophrenia and bipolar disorder.

Authors:  S Kristian Hill; Margret S H Harris; Ellen S Herbener; Mani Pavuluri; John A Sweeney
Journal:  Schizophr Bull       Date:  2008-04-29       Impact factor: 9.306

8.  The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

Authors:  Robert S Kern; Keith H Nuechterlein; Michael F Green; Lyle E Baade; Wayne S Fenton; James M Gold; Richard S E Keefe; Raquelle Mesholam-Gately; Jim Mintz; Larry J Seidman; Ellen Stover; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

9.  Cognition-enhancing and anxiolytic effects of memantine.

Authors:  Rimante Minkeviciene; Pradeep Banerjee; Heikki Tanila
Journal:  Neuropharmacology       Date:  2008-02-29       Impact factor: 5.250

Review 10.  Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.

Authors:  Chris G Parsons; Albrecht Stöffler; Wojciech Danysz
Journal:  Neuropharmacology       Date:  2007-08-10       Impact factor: 5.250

View more
  43 in total

1.  Severe cross-modal object recognition deficits in rats treated sub-chronically with NMDA receptor antagonists are reversed by systemic nicotine: implications for abnormal multisensory integration in schizophrenia.

Authors:  Derek L Jacklin; Amit Goel; Kyle J Clementino; Alexander W M Hall; John C Talpos; Boyer D Winters
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  Effects of the noncompetitive N-methyl-d-aspartate receptor antagonists ketamine and MK-801 on pain-stimulated and pain-depressed behaviour in rats.

Authors:  T M Hillhouse; S S Negus
Journal:  Eur J Pain       Date:  2016-02-23       Impact factor: 3.931

3.  Effects of the noncompetitive N-methyl-D-aspartate receptor antagonist ketamine on visual signal detection performance in rats.

Authors:  Todd M Hillhouse; Christina R Merritt; Joseph H Porter
Journal:  Behav Pharmacol       Date:  2015-08       Impact factor: 2.293

4.  Cross-site strain comparison of pharmacological deficits in the touchscreen visual discrimination test.

Authors:  Eric G Mohler; Zhiyong Ding; Lynne E Rueter; Douglas Chapin; Damon Young; Rouba Kozak
Journal:  Psychopharmacology (Berl)       Date:  2015-07-17       Impact factor: 4.530

Review 5.  Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research.

Authors:  Maria R Dauvermann; Graham Lee; Neil Dawson
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

6.  NMDA receptor antagonists distort visual grouping in rats performing a modified two-choice visual discrimination task.

Authors:  Katja Clarissa Ward; Halima Zainab Khattak; Louise Richardson; Jonathan Loon Choon Lee; Martin Vreugdenhil
Journal:  Psychopharmacology (Berl)       Date:  2013-05-07       Impact factor: 4.530

7.  Profile of cortical N-methyl-D-aspartate receptor subunit expression associates with inherent motor impulsivity in rats.

Authors:  Brionna D Davis-Reyes; Veronica M Campbell; Michelle A Land; Holly L Chapman; Susan J Stafford; Noelle C Anastasio
Journal:  Biochem Pharmacol       Date:  2019-07-08       Impact factor: 5.858

8.  Behavioral pharmacology of the odor span task: Effects of flunitrazepam, ketamine, methamphetamine and methylphenidate.

Authors:  Mark Galizio; Brooke April; Melissa Deal; Andrew Hawkey; Danielle Panoz-Brown; Ashley Prichard; Katherine Bruce
Journal:  J Exp Anal Behav       Date:  2016-10-17       Impact factor: 2.468

9.  Crocins, the active constituents of Crocus Sativus L., counteracted ketamine-induced behavioural deficits in rats.

Authors:  Georgia Georgiadou; Vasilios Grivas; Petros A Tarantilis; Nikolaos Pitsikas
Journal:  Psychopharmacology (Berl)       Date:  2013-10-06       Impact factor: 4.530

10.  Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task.

Authors:  Daniel Scott; Jane R Taylor
Journal:  Behav Brain Res       Date:  2013-11-14       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.